Kinpeygo for the treatment of primary immunoglobulin A nephropathy

Kinpeygo (budesonide) is a corticosteroid‐based therapy approved for the treatment of adults with rapidly progressing primary immunoglobulin A nephropathy. This article discusses its mode of action, efficacy and adverse effects.

Publication Details

Journal
Prescriber
Published
2024-09-01
DOI
https://doi.org/10.1002/psb.2151
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Kinpeygo for the treatment of primary immunoglobulin A nephropathy

Prescriber
Renal Diseases and Glomerulopathies
article

Kinpeygo for the treatment of primary immunoglobulin A nephropathy

article en

Abstract

Kinpeygo (budesonide) is a corticosteroid‐based therapy approved for the treatment of adults with rapidly progressing primary immunoglobulin A nephropathy. This article discusses its mode of action, efficacy and adverse effects.

PrescriberVol. 35(5)
Openalex Percentile: Top 81%
Renal Diseases and Glomerulopathies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Kinpeygo for the treatment of primary immunoglobulin A nephropathy · Prescriber (2024) | TGRS Research Map | TGRS